CL2011000431A1 - Compuestos derivados de 1-h-imidazo((4,5-c) o (1,2-a)-quinolina, (1,2,4)triazolo((4,3-a) o (1,5-c)-quinoxolina, entre otrois; composicion framaceutica, inhibidores de histamina, utiles en el tratamiento de pruritos, eczema, dermatitis, asma, rinitis, entre otros. - Google Patents
Compuestos derivados de 1-h-imidazo((4,5-c) o (1,2-a)-quinolina, (1,2,4)triazolo((4,3-a) o (1,5-c)-quinoxolina, entre otrois; composicion framaceutica, inhibidores de histamina, utiles en el tratamiento de pruritos, eczema, dermatitis, asma, rinitis, entre otros.Info
- Publication number
- CL2011000431A1 CL2011000431A1 CL2011000431A CL2011000431A CL2011000431A1 CL 2011000431 A1 CL2011000431 A1 CL 2011000431A1 CL 2011000431 A CL2011000431 A CL 2011000431A CL 2011000431 A CL2011000431 A CL 2011000431A CL 2011000431 A1 CL2011000431 A1 CL 2011000431A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- pruritus
- eczema
- rhinitis
- asthma
- Prior art date
Links
- 201000004624 Dermatitis Diseases 0.000 title abstract 3
- 208000003251 Pruritus Diseases 0.000 title abstract 2
- 208000006673 asthma Diseases 0.000 title abstract 2
- 208000010668 atopic eczema Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 206010039083 rhinitis Diseases 0.000 title abstract 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 title 1
- 229960001340 histamine Drugs 0.000 title 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 206010015943 Eye inflammation Diseases 0.000 abstract 1
- 102000000543 Histamine Receptors Human genes 0.000 abstract 1
- 108010002059 Histamine Receptors Proteins 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9582608P | 2008-09-10 | 2008-09-10 | |
| US23174909P | 2009-08-06 | 2009-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011000431A1 true CL2011000431A1 (es) | 2012-01-20 |
Family
ID=42005738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011000431A CL2011000431A1 (es) | 2008-09-10 | 2011-02-28 | Compuestos derivados de 1-h-imidazo((4,5-c) o (1,2-a)-quinolina, (1,2,4)triazolo((4,3-a) o (1,5-c)-quinoxolina, entre otrois; composicion framaceutica, inhibidores de histamina, utiles en el tratamiento de pruritos, eczema, dermatitis, asma, rinitis, entre otros. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20100120741A1 (enExample) |
| EP (1) | EP2324029A4 (enExample) |
| JP (1) | JP2012502067A (enExample) |
| KR (1) | KR20110095857A (enExample) |
| CN (1) | CN102388044A (enExample) |
| AR (1) | AR073574A1 (enExample) |
| AU (1) | AU2009291719A1 (enExample) |
| CA (1) | CA2735369A1 (enExample) |
| CL (1) | CL2011000431A1 (enExample) |
| MX (1) | MX2011002264A (enExample) |
| RU (1) | RU2011113419A (enExample) |
| TW (1) | TW201024297A (enExample) |
| UY (1) | UY32111A (enExample) |
| WO (1) | WO2010030785A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004031656A1 (de) * | 2004-06-30 | 2006-01-19 | Merck Patent Gmbh | Tetrahydrochinoline |
| MX2010009738A (es) | 2008-03-03 | 2010-09-30 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de tlr. |
| TWI547522B (zh) | 2009-07-07 | 2016-09-01 | 愛爾康研究有限公司 | 環氧乙烷環氧丁烷嵌段共聚物組成物 |
| US20110065698A1 (en) * | 2009-08-26 | 2011-03-17 | Cylene Pharmaceuticals, Inc. | Novel protein kinase modulators |
| JP2013053070A (ja) * | 2009-11-06 | 2013-03-21 | Takeda Chem Ind Ltd | ジヒドロピロロキノリン誘導体 |
| TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| DE102010025786A1 (de) * | 2010-07-01 | 2012-01-05 | Merck Patent Gmbh | Pyrazolochinoline |
| TW201206936A (en) | 2010-07-19 | 2012-02-16 | Alcon Res Ltd | Methods and compositions for the treatment of allergy |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| EP2699572B1 (en) * | 2011-04-21 | 2016-08-10 | Origenis GmbH | Heterocyclic compounds as kinase inhibitors |
| WO2013039785A2 (en) | 2011-09-12 | 2013-03-21 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| RS57854B1 (sr) | 2011-09-30 | 2018-12-31 | C&C Res Lab | Novi heterociklični derivati i njihove upotrebe |
| IN2014KN00948A (enExample) * | 2011-10-04 | 2015-08-21 | Janus Biotherapeutics Inc | |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| WO2014060113A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Novel kinase inhibitors |
| US9255105B2 (en) * | 2012-12-06 | 2016-02-09 | Enaltec Labs Private Limited | Process of preparing alcaftadine |
| BR122021012629B1 (pt) | 2013-02-01 | 2022-06-07 | Wellstat Therapeutics Corporation | Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos |
| AU2014236606A1 (en) * | 2013-03-15 | 2015-09-24 | Epigenetix, Inc. | Oxazolo(5,4-c)quinolin-2-one compounds as bromodomain inhibitors |
| AU2013394970B2 (en) * | 2013-07-25 | 2017-11-23 | Centre National De La Recherche Scientifique | Pyrroloquinoline derivatives as 5-HT6 antagonists, preparation method and use thereof |
| US10688082B2 (en) | 2015-06-11 | 2020-06-23 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with A2A antagonist properties |
| KR102070265B1 (ko) * | 2017-01-26 | 2020-01-28 | 한국화학연구원 | 신규한 [1,2,4]트리아졸로[4,3-a]퀴녹살린 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 BET 단백질 관련 질환의 예방 또는 치료용 약학적 조성물 |
| WO2019177971A1 (en) * | 2018-03-12 | 2019-09-19 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
| WO2019200500A1 (zh) | 2018-04-15 | 2019-10-24 | 苏州大学张家港工业技术研究院 | 1,2,4-三氮唑及其制备方法 |
| WO2019206242A1 (zh) * | 2018-04-27 | 2019-10-31 | 北京鼎材科技有限公司 | 有机电致发光材料及器件 |
| TW202021969A (zh) * | 2018-05-31 | 2020-06-16 | 南韓商Ｃ＆Ｃ新藥研究所 | 雜環衍生物及其用途 |
| CN109705141B (zh) * | 2019-02-20 | 2020-05-29 | 苏州大学 | 一种恶唑并喹啉类化合物及其制备方法与应用 |
| WO2021098734A1 (zh) * | 2019-11-19 | 2021-05-27 | 南京明德新药研发有限公司 | 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用 |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| WO2022047093A1 (en) | 2020-08-28 | 2022-03-03 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of kras |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
| US12077539B2 (en) | 2021-03-22 | 2024-09-03 | Incyte Corporation | Imidazole and triazole KRAS inhibitors |
| EP4067357A1 (en) * | 2021-03-30 | 2022-10-05 | JW Pharmaceutical Corporation | Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate |
| CA3224674A1 (en) | 2021-07-07 | 2023-01-12 | Pei Gan | Tricyclic compounds as inhibitors of kras |
| EP4396187A1 (en) | 2021-08-31 | 2024-07-10 | Incyte Corporation | Naphthyridine compounds as inhibitors of kras |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| WO2023056421A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| CR20240197A (es) | 2021-10-14 | 2024-08-07 | Incyte Corp | Compuestos de quinolina como inhibidores de kras |
| CN116969943A (zh) * | 2022-04-28 | 2023-10-31 | 轩竹生物科技股份有限公司 | 三并环类二酰甘油激酶抑制剂及其用途 |
| US20250382296A1 (en) * | 2022-08-03 | 2025-12-18 | Abbisko Therapeutics Co., Ltd. | Nitrogen-containing fused three ring prmt5 inhibitor, and preparation method therefor and pharmaceutical use thereof |
| JP2025533677A (ja) | 2022-09-26 | 2025-10-07 | 上海湃隆生物科技有限公司 | 新型ｐｒｍｔ５阻害剤およびその使用 |
| EP4594520A2 (en) | 2022-09-30 | 2025-08-06 | Sixfold Bioscience Ltd. | Compositions containing oligonucleotides with theranostic applications |
| CN116332789A (zh) * | 2023-03-10 | 2023-06-27 | 上海康鹏科技股份有限公司 | 一种4-氨基-2-氟苯甲酰胺的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4053600A (en) * | 1973-03-08 | 1977-10-11 | Sandoz, Inc. | Tricyclic 1,2,4-triazolo-quinazolines |
| US4495187A (en) * | 1982-10-18 | 1985-01-22 | Pfizer Inc. | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents |
| IN160956B (enExample) * | 1982-10-18 | 1987-08-22 | Pfizer | |
| EP1050535A4 (en) * | 1997-11-11 | 2001-04-25 | Ono Pharmaceutical Co | CONDENSED PYRAZINE DERIVATIVES |
| NZ533682A (en) * | 2001-12-21 | 2007-06-29 | Jsw Res Forschungslabor Gmbh | Pyrazolyl-substituted triazoloquinoxalines |
| WO2008031556A2 (en) * | 2006-09-12 | 2008-03-20 | Ucb Pharma, S.A. | 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions |
| EP1972629A1 (en) * | 2007-03-23 | 2008-09-24 | Mutabilis SA | New imidazolo-heteroaryl derivatives with antibacterial properties |
| FR2921927B1 (fr) * | 2007-10-03 | 2012-10-12 | Univ De Montpellier 1 | Imidazo°1,2-a!quinoxalines et derives pour le traitement des cancers |
-
2009
- 2009-09-10 JP JP2011526310A patent/JP2012502067A/ja active Pending
- 2009-09-10 WO PCT/US2009/056519 patent/WO2010030785A2/en not_active Ceased
- 2009-09-10 AU AU2009291719A patent/AU2009291719A1/en not_active Abandoned
- 2009-09-10 KR KR1020117008096A patent/KR20110095857A/ko not_active Withdrawn
- 2009-09-10 CA CA2735369A patent/CA2735369A1/en not_active Abandoned
- 2009-09-10 US US12/556,866 patent/US20100120741A1/en not_active Abandoned
- 2009-09-10 AR ARP090103487A patent/AR073574A1/es not_active Application Discontinuation
- 2009-09-10 RU RU2011113419/04A patent/RU2011113419A/ru not_active Application Discontinuation
- 2009-09-10 EP EP09813607A patent/EP2324029A4/en not_active Withdrawn
- 2009-09-10 TW TW098130500A patent/TW201024297A/zh unknown
- 2009-09-10 UY UY0001032111A patent/UY32111A/es not_active Application Discontinuation
- 2009-09-10 CN CN2009801427590A patent/CN102388044A/zh active Pending
- 2009-09-10 MX MX2011002264A patent/MX2011002264A/es not_active Application Discontinuation
-
2011
- 2011-02-28 CL CL2011000431A patent/CL2011000431A1/es unknown
- 2011-11-21 US US13/301,131 patent/US20120065187A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009291719A1 (en) | 2010-03-18 |
| US20120065187A1 (en) | 2012-03-15 |
| KR20110095857A (ko) | 2011-08-25 |
| US20100120741A1 (en) | 2010-05-13 |
| UY32111A (es) | 2010-04-30 |
| JP2012502067A (ja) | 2012-01-26 |
| AR073574A1 (es) | 2010-11-17 |
| RU2011113419A (ru) | 2012-10-20 |
| EP2324029A4 (en) | 2011-09-14 |
| TW201024297A (en) | 2010-07-01 |
| CN102388044A (zh) | 2012-03-21 |
| MX2011002264A (es) | 2011-05-23 |
| WO2010030785A3 (en) | 2010-07-01 |
| WO2010030785A2 (en) | 2010-03-18 |
| CA2735369A1 (en) | 2010-03-18 |
| EP2324029A2 (en) | 2011-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011000431A1 (es) | Compuestos derivados de 1-h-imidazo((4,5-c) o (1,2-a)-quinolina, (1,2,4)triazolo((4,3-a) o (1,5-c)-quinoxolina, entre otrois; composicion framaceutica, inhibidores de histamina, utiles en el tratamiento de pruritos, eczema, dermatitis, asma, rinitis, entre otros. | |
| CY2024019I1 (el) | Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)- 5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες | |
| CL2011000480A1 (es) | Compuestos derivados de amino-1,2,4-triazolo[1,5-a]piridina sustituidos, inhibidores de quinasa; composicion farmaceutica; y su uso para el tratamiento o prevencion de condiciones inflamatorias, inmunologicas, autoinmunes, alergicas, reumaticas, tromboticas, cancer, infecciones, padecimientos neurodegenerativos, entre otras. | |
| UY32967A (es) | Compuestos heterocíclicos fusionados como moduladores del receptor de la orexina | |
| CL2008003096A1 (es) | Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras. | |
| CL2011001361A1 (es) | Compuestos derivados de n-(imidazo[1,2-a]pirazin-8-il)-1h-amina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades mediadas por inhiibicion de actividad syk, tales como cancer, trastornos alergicos o inflamatorios. | |
| CL2012001027A1 (es) | Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek. | |
| UY33265A (es) | Composiciones sólidas que comprenden (2R, 6S, 13aS, 14aR, 16aS,z)-N-(ciclopropilsulfonil)-6-(5-metilpirazin-2-carboxamido)-5, 16-dioxo-2-(fenantridin-6-iloxi)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecin-14a-carboxamida para su uso como inhibidores del HCV y proceso para su preparación | |
| CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
| SV2010003642A (es) | Compuestos | |
| CL2012001745A1 (es) | Compuestos derivados de pirrolidinonas heteroaromáticas fusionadas con actividad inhibitoria de tirosina quinasa esplénica; composición farmacéutica que los comprende; uso en el tratamiento de la rinitis alérgica, asma, dermatitis atópica, lupus eritematoso sistémico, artritis reumatoide, psoriasis, epoc, entre otras | |
| CL2008001345A1 (es) | Compuestos derivados de imidazo[1,2-b]piridazinas, inhibidores de cinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su proceso de preparacion; y su uso en enfermedades hiperproliferativas, inflamatorias, alergicas y obstructivas de las vias respiratorias, entre otras. | |
| CL2011002056A1 (es) | Compuestos derivados del acido {7-([1,2,3]triazol-1-il)-6,7,8,9-tetrahidropirido[1,2-a]indol-10-il}-acetico, antagonista del receptor crth2; composicion farmaceutica que lo comprende; utiles ene l tratamiento del asma, alergias, cancer entre otras. | |
| PE20130457A1 (es) | INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT | |
| CL2012002270A1 (es) | Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer. | |
| ECSP088906A (es) | PIRAZOLO 1,5-a PIRIMIDINAS | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CL2013002063A1 (es) | Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune. | |
| CL2008001745A1 (es) | Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer. | |
| CL2014001103A1 (es) | Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros. | |
| NZ607966A (en) | Quinoline and quinoxaline derivatives as kinase inhibitors | |
| CL2015002386A1 (es) | Nuevos octahidro-pirrolo[3,4-c)-pirrol y -piridina-fenilo. | |
| EA201100079A1 (ru) | Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора | |
| CL2007001555A1 (es) | Compuestos derivados de 4-amino-pirido[3,2-e]pirazinas; inhibidores de fosfodiesterasa 10 (pde10); procedimeinto de preparacion; composicion framaceutica; combinacion farmaceutica, y sus uso en el tratamiento de trastornos neurologicos y psiquiatricos, tales como esquizofrenia y otros trastornos psicoticos. | |
| CL2011002837A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostericos positivos de receptores mglur2; composicion farmaceutica; proceso para prepararla; y su uso en el tratamiento o la prevencion de un trastorno del sistema nervioso central tal como la ansiedad, esquizofrenia y migraña, entre otros. |